+ |
bortezomib | down-regulates activity
chemical inhibition
|
PSMD2 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259313 |
|
|
Homo sapiens |
Myeloma Cell |
pmid |
sentence |
21504411 |
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib (Velcade®) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
bortezomib | down-regulates activity
chemical inhibition
|
PSMB1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259306 |
|
|
Homo sapiens |
Myeloma Cell |
pmid |
sentence |
21504411 |
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib (Velcade®) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
bortezomib | down-regulates activity
chemical inhibition
|
PSMD1 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259312 |
|
|
Homo sapiens |
Myeloma Cell |
pmid |
sentence |
21504411 |
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib (Velcade®) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
bortezomib | down-regulates activity
chemical inhibition
|
PSMB2 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259309 |
|
|
Homo sapiens |
Myeloma Cell |
pmid |
sentence |
21504411 |
Proteasome inhibition is a modern and surprisingly successful approach how to cancer treatment. Bortezomib (Velcade®) is a first-in-class proteasome inhibitor and has been approved for first-line treatment of multiple myeloma and second-line treatment of mantle cell lymphoma. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
bortezomib | down-regulates activity
chemical inhibition
|
PSMB5 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-257820 |
|
|
Homo sapiens |
HeLa Cell |
pmid |
sentence |
19428245 |
MG-132, which was one of the first synthetic inhibitors, interacts reversibly with the N-terminal threonine residue of the β5 active site. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |